查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933849

胃部空间占用装置市场（按产品类型、给药途径、安装週期、最终用户和分销管道划分），全球预测，2026-2032年

Gastric Space-Occupying Device Market by Product Type, Route Of Administration, Duration Of Placement, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年胃定位装置市值为 3.2582 亿美元，预计到 2026 年将成长至 3.6311 亿美元，预计到 2032 年将达到 8.1045 亿美元，复合年增长率为 13.90%。

关键市场统计数据
基准年 2025 3.2582亿美元
预计年份：2026年 3.6311亿美元
预测年份 2032 8.1045亿美元
复合年增长率 (%) 13.90%

本文全面介绍了临床需求、医疗设备创新和不断变化的照护流程如何重塑医疗器材的采纳和策略重点。

当侵入性手术并非首选或迫在眉睫的治疗方案时，胃占位装置正日益被视为肥胖和代谢性疾病综合治疗策略的重要组成部分。这些装置旨在减少胃容量并改变饱腹感讯号，在药物治疗和减重手术之间占据着独特的临床定位，推动了内视镜室、门诊中心和专科诊所等多种诊疗模式的创新。与侵入性更强的治疗方案相比，这些装置具有可逆性、可调控的治疗方案以及更低的手术全期併发症，因此更受临床医生的青睐，这也影响着市场需求和临床应用模式。

对正在重新定义医疗器材设计和医疗服务路径的技术、临床、监管和病患偏好趋势进行策略分析

由于装置设计、输送技术和以患者为中心的护理模式的同步进步，胃内装置领域正经历着变革性的转变。设计人员不断改进装置几何形状，包括可调节机制和混合液气结构，以提高耐受性和治疗控制。同时，可吞嚥装置凭藉其微创的输送方式，正挑战内视镜置入的优势。这些技术变革也伴随着手术流程从医院向门诊手术中心和专科诊所的转移，从而为降低成本、加快患者周转率和扩大地域覆盖创造了机会。

本文检验不断变化的关税政策如何重塑医疗设备供应链的采购、製造决策和商业性韧性。

美国新关税政策的实施对依赖一体化国际供应链的医疗设备製造商、供应商和下游医疗服务提供者产生了重大影响。关税调整增加了从海外采购的零件和组件的投入成本，可能挤压製造商的利润空间，并促使其在竞争激烈的竞标环境中进行价格调整。更重要的是，关税也在改变策略采购决策，促使供应商和製造商重新检视供应商合约、探索近岸外包方案或整合采购量以降低关税风险。

一份详细的細項分析报告，阐述了产品形态、护理环境、交付管道、分销模式和安装週期如何相互作用，从而影响商业化策略。

分析这种细分市场的细微差别，可以发现影响产品设计、市场推广策略和临床定位的许多因素。依产品类型分析，可调式装置、双液/气配置、单液填充式和单气填充式装置之间的差异，造就了不同的临床应用情境。可调式装置提供渐进式治疗控制，适合需要个人化治疗的患者，而单液或单气填充式装置则可能优先考虑操作简单性和降低装置复杂性。这些产品层面的差异会波及临床训练需求、装置使用寿命考量以及病患咨询通讯协定。

分析监管、报销和临床基础设施方面的区域差异，以确定区域引进路径和市场进入策略。

区域趋势反映了美洲、欧洲、中东和非洲以及亚太地区在法规结构、临床基础设施、支付方优先事项和患者人口结构方面的差异。在美洲，成熟的内视镜网路、高普及率的专业减重手术计画以及日益认可微创手术的报销环境，为先进器械的研发和长期疗效研究创造了有利条件。儘管商业化路径可能较为复杂，但成熟的临床试验网络和集中式卓越中心能够加速实证医学证据的产生和推广​​应用。

公司策略行动和竞争优势，展现了产品蓝图、证据规划和供应链敏捷性如何创造永续优势。

该领域的领导企业透过互补策略脱颖而出，这些策略融合了产品创新、实证实践和策略伙伴关係。成功的公司倾向于投资模组化产品路线图，以便在保持蓝图连续性的同时，逐步改进产品，例如优化给药系统、增强可调控制功能和整合监测。这种方法缩短了迭代升级的上市时间，并能够建立更有针对性的临床医生回馈机制，从而优化使用者体验。

这是一份实用指南，旨在协调产品开发、临床证据、供应链韧性和市场进入，从而推动创新并实现规模化应用。

产业领导者应优先进行一系列协作，协调工程、临床、商业和监管职能，以加速产品推广应用并降低市场风险。首先，将实证策略融入产品开发，结合临床终点、病患报告结局和卫生经济学终点，向支付者和医疗服务提供者证明产品价值。其次，推行模组化工程，以支援可扩展的混合产品变体，同时最大限度地减少增量更新带来的监管负担。

我们采用透明、多方面的研究途径，结合临床医师访谈、文献综述、监管图谱和技术格局分析，以指导策略选择。

本分析整合了多种调查方法，以确保其稳健性和对策略决策的相关性。主要研究包括对临床医生、采购人员和医疗设备开发人员进行结构化访谈，以收集关于手术流程、器械偏好和临床证据期望的真实世界观点。次要研究包括对同行评审的临床文献、监管指导文件和已发布的手术操作指南进行系统性回顾，以根据目前的临床标准和安全考虑得出研究结果。

综合分析总结表明，临床创新、营运准备和报销策略必须保持一致，才能确保持续的商业成功。

累积的证据表明，胃部占位装置正处于一个转折点。技术创新、医疗服务模式的变革以及支付方的期望相互交织，既带来了机会，也带来了挑战。具备可调控制、操作简便、安全性明确的装置最能满足临床医师和病患的需求，而能够减轻手术负担的给药途径则有助于扩大病患群体。同时，区域监管差异以及关税带来的供应链压力，要求制定周密的策略规划，以避免执行过程中出现失误。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的胃腔占位装置市场

  • 可调节的
  • 两种液体和气体类型
  • 单液填充型
  • 单气填充型

9. 依给药途径分類的胃腔占位装置市场

  • 内视镜
  • 口服型

10. 依留置时间分類的胃腔占位装置市场

  • 长期
  • 短期

11. 依最终用户分類的胃腔占位装置市场

  • 门诊手术中心
  • 肥胖治疗诊所
  • 医院

12. 依分销管道分類的胃腔占位装置市场

  • 直销
  • 经销商

第十三章 胃腔占位装置市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 胃腔占位装置市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国胃腔占位装置市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国胃部空间占用装置市场

第十七章 中国胃占位装置市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Allurion Technologies, Inc.
  • Apollo Endosurgery, Inc.
  • BaroNova Therapeutics
  • Districlass Medical
  • Endalis
  • Endogastric Solutions
  • Fengh Medical
  • G-Surgery
  • Helioscopie Medical Implants
  • Lexel Medical
  • Life Partners Europe
  • Medicone
  • Medsil
  • Obalon Therapeutics, Inc.
  • Phagia Technologies
  • ReShape Lifesciences Inc.
  • Silimed
  • Silimed Ltda
  • Spatz Medical Ltd.
  • Tulip Medical
Product Code: MRR-C36616F6997F

The Gastric Space-Occupying Device Market was valued at USD 325.82 million in 2025 and is projected to grow to USD 363.11 million in 2026, with a CAGR of 13.90%, reaching USD 810.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 325.82 million
Estimated Year [2026] USD 363.11 million
Forecast Year [2032] USD 810.45 million
CAGR (%) 13.90%

Comprehensive introduction outlining how clinical needs, device innovations, and care pathway shifts are reshaping adoption and strategic priorities

Gastric space-occupying devices are increasingly recognized as a component of multidisciplinary strategies for managing obesity and metabolic disease where invasive surgery may not be the immediate or preferred option. These devices, designed to reduce gastric volume and alter satiety signaling, occupy a distinct clinical niche between pharmacotherapy and bariatric surgery and are driving new care pathways across endoscopy suites, ambulatory centers, and specialized clinics. Clinicians are attracted to options that offer reversible effects, adjustable therapeutic profiles, and reduced peri-procedural morbidity relative to more invasive alternatives, which in turn shapes demand and clinical adoption patterns.

From a development perspective, innovation is converging on device ergonomics, delivery mechanisms, and materials that optimize patient comfort, ease of implantation and removal, and durability for intended durations of placement. Parallel advances in procedural practice and training-particularly in endoscopic techniques-have reduced procedural variability and expanded the cohort of physicians able to offer these therapies. As a result, payers, providers, and manufacturers are re-evaluating pathways to evidence generation, long-term follow-up, and value demonstration to ensure these devices align with evolving standards of care and reimbursement criteria.

Taken together, the introduction of new device formats and the migration of procedures into lower-acuity settings are reshaping clinical workflows and commercial strategies. Stakeholders should consider how clinical evidence, user experience, and cost-efficiency will jointly determine the trajectory of adoption in the coming years.

Strategic analysis of converging technological, clinical, regulatory, and patient preference trends that are redefining device design and care delivery pathways

The gastric device landscape is undergoing transformative shifts driven by simultaneous advances in device design, delivery techniques, and patient-centered care models. Designers are iterating on form factors that include adjustable mechanisms and hybrid fluid-gas constructs to improve tolerability and therapeutic control, while swallowable devices are challenging the primacy of endoscopic placement by offering less invasive administration. These technical shifts are complemented by procedural migration from hospitals to ambulatory surgical centers and specialized clinics, creating opportunities for cost reduction, faster patient throughput, and broader geographic access.

Regulatory trends are also influencing strategic decisions. Regulators are increasingly emphasizing robust post-market surveillance and real-world evidence to support claims, encouraging manufacturers to integrate monitoring and data capture capabilities into device ecosystems. Payer requirements are evolving toward outcomes-based reimbursement models in which long-term effectiveness and safety evidence will be critical. Concurrently, patient expectations now favor minimally disruptive interventions that fit into outpatient workflows and deliver measurable improvements in quality of life, which has heightened the focus on device comfort, ease of use, and reversible options.

Collectively, these forces are prompting manufacturers to pursue differentiated clinical programs, modular product portfolios, and partnerships that accelerate access to lower-acuity settings. Companies that align engineering innovation with evidence generation and clear reimbursement pathways will be best positioned to capitalize on the shift toward less invasive obesity management solutions.

Focused examination of how evolving tariff policies are reshaping sourcing, manufacturing decisions, and commercial resilience across the device supply chain

The introduction of new tariff policies in the United States has created material implications for device manufacturers, suppliers, and downstream providers that rely on integrated international supply chains. Tariff adjustments raise input costs for components and subassemblies sourced from overseas, which can compress manufacturer margins or prompt price adjustments that are sensitive in competitive procurements and tender environments. Importantly, tariffs also alter strategic sourcing calculus, incentivizing suppliers and manufacturers to reassess vendor contracts, explore nearshoring options, or consolidate purchasing volumes to mitigate customs exposure.

Manufacturers facing increased landed costs must weigh responses that include absorption of cost increases, selective price increases, or engineering redesigns to source alternative materials. Each option carries trade-offs: absorbing costs affects profitability and potential reinvestment in clinical programs; price increases may reduce competitiveness in payor negotiations and procurement cycles; redesigns require time and regulatory clarity to avoid disruptions. Moreover, device companies with vertically integrated manufacturing outside tariff jurisdictions may gain short-term advantages, while pure-play importers may encounter margin pressure and inventory valuation impacts.

Beyond direct cost effects, tariffs influence investment decisions around capacity expansion, contract manufacturing relationships, and inventory strategies. Firms may pursue diversified supplier networks and inventory pre-positioning to maintain service levels, while others may accelerate localization of production to preserve pricing flexibility. Ultimately, organizations that proactively model tariff scenarios, adjust procurement strategies, and communicate transparently with clinical and commercial partners will be better positioned to navigate the cumulative effects on supply continuity and competitive dynamics.

In-depth segmentation insights explaining how product form, care setting, delivery route, distribution model, and placement duration interact to shape commercialization strategies

A nuanced view of segmentation reveals multiple vectors that inform product design, go-to-market strategy, and clinical positioning. When analyzed by product type, distinctions among adjustable devices, dual fluid-gas constructions, single fluid-filled formats, and single gas-filled options drive divergent clinical use cases; adjustable devices offer titratable therapeutic control suited to patients requiring individualized therapy, while single fluid or gas-filled designs may prioritize procedural simplicity and lower device complexity. These product-level differences cascade into clinical training needs, device lifespan considerations, and patient counseling protocols.

End-user segmentation between ambulatory surgical centers, bariatric clinics, and hospitals affects procurement cycles, capital equipment considerations, and procedural throughput expectations. Ambulatory surgical centers frequently emphasize efficiency and day-case recovery, making compact delivery systems and short procedure durations especially valuable, whereas hospitals may prioritize integration with complex comorbidity management programs. Route of administration divides the market into endoscopic and swallowable solutions, each with distinct clinical pathways, risk profiles, and practitioner skill sets; swallowable devices expand access by minimizing procedural sedation, while endoscopic devices allow direct visualization and retrieval control.

Distribution channel choices between direct sales and distributor partnerships influence market reach and service expectations. Direct sales models can facilitate closer clinical training and data collection but require investment in field resources, whereas distributor relationships can accelerate geographic penetration with lower fixed costs. Duration of placement, whether long-term or short-term, affects follow-up scheduling, surveillance protocols, and outcome metrics, demanding clear labeling, patient education, and evidence tailored to each intended use horizon. Integrating these segmentation layers into product and commercial planning yields strategies that align clinical utility with distribution and reimbursement realities.

Cross-regional analysis of regulatory, reimbursement, and clinical infrastructure differences that determine localized adoption pathways and market access tactics

Regional dynamics reflect differences in regulatory frameworks, clinical infrastructure, payer priorities, and patient demographics across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, established endoscopy networks, a high prevalence of specialized bariatric programs, and a reimbursement environment that increasingly recognizes minimally invasive interventions create fertile conditions for advanced device formats and long-term outcome studies. While commercialization pathways may be complex, the maturity of clinical trial networks and centralized centers of excellence can accelerate evidence generation and adoption.

Europe, Middle East & Africa presents heterogeneous regulatory pathways and payer landscapes that require localized market access strategies. Countries with centralized health technology assessments emphasize cost-effectiveness and long-term outcomes, prompting manufacturers to develop region-specific clinical dossiers and engage early with payers. The Middle East and parts of Africa show growing interest in minimally invasive obesity interventions, driven by rising obesity prevalence and investments in specialty care, but uptake is contingent on training and infrastructure development.

Asia-Pacific includes markets with rapidly expanding endoscopy capacity, variable reimbursement structures, and distinct patient and clinician preferences that favor less invasive, cost-efficient options. Several markets within the region prioritize domestic manufacturing and regulatory pathways that emphasize local data, which can affect market entry sequencing. Overall, regional approaches must balance global evidence packages with local clinical, regulatory, and commercial adaptation to drive sustainable adoption.

Corporate strategic behaviors and competitive differentiators demonstrating how product roadmaps, evidence programs, and supply chain agility create sustainable advantages

Leading organizations in the space are differentiating through complementary strategies that combine product innovation, evidence generation, and strategic partnerships. Successful actors tend to invest in modular product roadmaps that allow incremental improvements-such as enhanced delivery systems, adjustable controls, and integrated monitoring-while preserving regulatory continuity. This approach reduces time to market for iterative upgrades and enables more targeted clinician feedback loops to refine user experience.

Clinical differentiation is frequently achieved through robust investigator-initiated studies, registry development, and long-term surveillance programs that substantiate safety and functional outcomes. Companies that prioritize prospective, real-world evidence collection gain stronger positioning with payers and providers seeking long-term performance data. In parallel, strategic commercial alliances with procedure service providers, training networks, and diagnostic partners extend reach into ambulatory and specialized clinic settings and enable bundled care models.

Manufacturing and supply chain strategies are also pivotal. Firms leveraging flexible contract manufacturing, localized assembly, or dual-sourcing can maintain supply continuity while controlling costs. Finally, those that align reimbursement and health economics teams early in development to craft payer narratives and value dossiers tend to achieve smoother access and uptake. Collectively, these company-level choices define competitive separation between product-centric players and integrated solutions providers.

Actionable playbook for aligning product development, clinical evidence, supply chain resilience, and market access to translate innovation into scalable adoption

Industry leaders should prioritize a coordinated set of actions that align engineering, clinical, commercial, and regulatory functions to accelerate adoption and mitigate market risk. First, integrate evidence strategy with product development by pairing clinical endpoints with patient-reported outcomes and health economic endpoints so that value is demonstrable to payers and providers. Second, pursue modular engineering that supports adjustable and hybrid product variants while minimizing regulatory burden for incremental updates.

Third, strengthen supply chain resilience by diversifying suppliers, evaluating nearshore manufacturing options, and developing inventory contingency plans to reduce exposure to trade policy volatility. Fourth, design go-to-market approaches that reflect heterogeneity in end users: tailor training and service models for ambulatory surgical centers and bariatric clinics while maintaining hospital-focused pathways for complex cases. Fifth, engage early with payers and HTA bodies to co-develop evidence requirements and reimbursement pathways, thereby reducing friction during commercial launch.

Finally, consider partnerships with clinical networks and diagnostic providers to bundle care solutions that simplify procurement and create measurable care pathways. Executing on these priorities requires governance mechanisms that ensure cross-functional accountability, timely decision-making, and iterative learning from post-market data. Organizations that adopt this integrated playbook will better convert technological advances into sustainable clinical and commercial outcomes.

Transparent and multi-method research approach combining clinician interviews, literature synthesis, regulatory mapping, and technical landscape analysis to inform strategic choices

This analysis synthesizes multiple methodological approaches to ensure robustness and relevance for strategic decision-making. Primary research included structured interviews with clinicians, procurement leaders, and device innovators to capture frontline perspectives on procedural workflows, device preferences, and clinical evidence expectations. Secondary research entailed a systematic review of peer-reviewed clinical literature, regulatory guidance documents, and published procedural practice guidelines to ground insights in contemporary clinical standards and safety considerations.

The research also incorporated a comparative regulatory analysis across key jurisdictions to map approval pathways, post-market surveillance requirements, and emerging payer expectations. Device design trends were assessed through technical literature and patent landscape scans to identify recurring innovation themes and potential blueprints for differentiation. To validate findings, triangulation was performed by cross-referencing interview insights with clinical registry data and public filings where available, ensuring consistency between practitioner-reported experiences and documented outcomes.

Finally, data quality controls included source validation, expert review cycles, and methodological transparency notes outlining limitations such as variability in regional reporting and the evolving nature of clinical evidence. These steps were undertaken to produce a defensible, actionable synthesis that supports strategic planning without relying on proprietary market estimates or forecasts.

Concluding synthesis emphasizing the imperative to align clinical innovation, operational readiness, and reimbursement strategies to secure sustained commercialization success

The cumulative findings underscore that gastric space-occupying devices are at an inflection point where engineering innovation, changing care delivery models, and payer expectations converge to create both opportunity and complexity. Devices that deliver adjustable control, simplified delivery, and clear safety profiles align most closely with clinician and patient preferences, while routes of administration that reduce procedural burden expand the addressable patient population. At the same time, regional regulatory diversity and tariff-driven supply chain pressures require deliberate strategic planning to avoid executional missteps.

Navigating this landscape successfully will depend on integrating evidence generation with product roadmaps, aligning distribution strategies to target end-user needs, and reinforcing supply chain flexibility to respond to policy-induced cost dynamics. Organizations that make early investments in real-world evidence infrastructure, payer engagement, and scalable training models will reduce time-to-adoption and strengthen reimbursement positioning. Conversely, firms that neglect these elements may find that promising technical advantages fail to translate into sustainable market penetration.

In sum, the sector is maturing from proof-of-concept innovation toward commercial-scale deployment, and stakeholders who balance clinical value, operational excellence, and market access readiness will lead the next wave of adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastric Space-Occupying Device Market, by Product Type

  • 8.1. Adjustable
  • 8.2. Dual Fluid-Gas
  • 8.3. Single Fluid-Filled
  • 8.4. Single Gas-Filled

9. Gastric Space-Occupying Device Market, by Route Of Administration

  • 9.1. Endoscopic
  • 9.2. Swallowable

10. Gastric Space-Occupying Device Market, by Duration Of Placement

  • 10.1. Long-Term
  • 10.2. Short-Term

11. Gastric Space-Occupying Device Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Bariatric Clinics
  • 11.3. Hospitals

12. Gastric Space-Occupying Device Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors

13. Gastric Space-Occupying Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gastric Space-Occupying Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gastric Space-Occupying Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Gastric Space-Occupying Device Market

17. China Gastric Space-Occupying Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Allurion Technologies, Inc.
  • 18.6. Apollo Endosurgery, Inc.
  • 18.7. BaroNova Therapeutics
  • 18.8. Districlass Medical
  • 18.9. Endalis
  • 18.10. Endogastric Solutions
  • 18.11. Fengh Medical
  • 18.12. G-Surgery
  • 18.13. Helioscopie Medical Implants
  • 18.14. Lexel Medical
  • 18.15. Life Partners Europe
  • 18.16. Medicone
  • 18.17. Medsil
  • 18.18. Obalon Therapeutics, Inc.
  • 18.19. Phagia Technologies
  • 18.20. ReShape Lifesciences Inc.
  • 18.21. Silimed
  • 18.22. Silimed Ltda
  • 18.23. Spatz Medical Ltd.
  • 18.24. Tulip Medical

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ADJUSTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ADJUSTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ADJUSTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DUAL FLUID-GAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DUAL FLUID-GAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DUAL FLUID-GAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE FLUID-FILLED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE FLUID-FILLED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE FLUID-FILLED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE GAS-FILLED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE GAS-FILLED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE GAS-FILLED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SWALLOWABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SWALLOWABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SWALLOWABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY LONG-TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SHORT-TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY BARIATRIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY BARIATRIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY BARIATRIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 106. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 124. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 130. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)